Company: Radius Health
Based: Cambridge, MA
Amount: $91M

Investors: BB Biotech AG, Brookside Capital, Saints Capital, Nordic Bioscience, Ipsen Pharma SAS, MPM Capital, BB Biotech Ventures, MPM Bio IV NVS Strategic Fund, The Wellcome Trust, HealthCare Ventures, Scottish Widows Investment Partnership, GE Capital and Healthcare Financial Services

Scoop: Back in May, Radius Health wrapped a $91 million financing round. The bulk of the money was slated to pay for a Phase III trial of BA058, a subcutaneous injection therapy for osteoporosis. The 18-month pivotal trial should provide the data needed to gain U.S. and European approval. Radius said at the time it was looking for a partner.

The round included $66 million in equity financing and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance to a $25 million multi-draw term loan facility. Five new investors, including BB Biotech AG, Brookside Capital, Saints Capital, Nordic Bioscience and Ipsen Pharma SAS joined existing investors MPM Capital, BB Biotech Ventures, MPM Bio IV NVS Strategic Fund, The Wellcome Trust, HealthCare Ventures and Scottish Widows Investment Partnership in the equity financing.

Related Articles:
Radius lands $91M, plans listing as it plots Ph3 osteoporosis drug trial
Radius Health - Top 20 VC deals of 2008
Emerging Drug Developer: Radius Health
Radius adds $15M to third venture round